Experimental CAR t therapy targets Hard-to-Treat cancers in first human trial

NCT ID NCT05568680

Recruiting now Disease control Sponsor: Verismo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new treatment called SynKIR-110 for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has spread or come back. The treatment involves taking a patient's own immune cells, engineering them in a lab to better recognize and attack cancer cells that have a protein called mesothelin, and then giving them back as a one-time infusion. The main goals are to see if it is safe and feasible, and to find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SynKIR-110 (a type of CAR T cell therapy made from the patient's own immune cells, engineered to target mesothelin on cancer cells)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced ovarian cancer, bile duct cancer, or mesothelioma that has not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 42 participants, so it is primarily testing safety, not effectiveness. The therapy may cause serious side effects like cytokine release syndrome or nerve problems, and it may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma fallopian tube cancer malignant epithelioid mesothelioma malignant mesothelioma Mesothelioma, Malignant ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA RECURRENT MESOTHELIOMA, MALIGNANT OVARIAN CANCER

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
University of Kansas Cancer Center
ACTIVE_NOT_RECRUITING

Westwood, Kansas, 66205, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.